Healthcare Industry News: NuVasive
News Release - November 15, 2018
NuVasive Launches First-Of-Its-Kind Brigade(R) Lateral Implant And Instrumentation Optimized For Lateral Anterior Lumbar Interbody Fusion Spine SurgerySAN DIEGO, Nov. 15, 2018 -- (Healthcare Sales & Marketing Network) -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the U.S. commercial launch of Brigade® Lateral, the industry's first interbody implant and instrumentation optimized for lateral anterior lumbar interbody fusion (ALIF) spine surgery.
NuVasive's Lateral ALIF™ is a proprietary spine procedure enabling access to L5-S1 from a lateral position, while retaining the characteristics of a traditional ALIF. Brigade Lateral features improved instrumentation, a new insertion method and an expanded lordotic implant offering, all optimized for improved workflow and outcomes through the Lateral ALIF procedure. The technology's threaded in-line inserter is angled off the midline and positioned on the lateral edge of the implant to better access the L5-S1 spine levels, which have typically been very difficult to treat effectively. The instrumentation is designed to offer surgeons a low-profile and reproducible insertion method, enhancing the overall surgical workflow in the operating room (OR). With a variety of lordotic implant options, Brigade Lateral allows surgeons to customize lordosis based on a patient's need which is important to preserving and restoring spinal alignment.
"The NuVasive Lateral ALIF procedure, coupled with the Brigade Lateral implant and instrumentation specifically designed for this approach, is a game changer for me and my patients," said Dr. Michael Cluck, orthopedic surgeon at Bay Area Spine Care in San Jose, California. "When used with minimally invasive surgical techniques, Lateral ALIF allows surgeons to complete a standard ALIF and posterior fixation from one position for both single-level and, more importantly, multi-level lumbar spinal fusions."
Lateral ALIF is integrated into NuVasive's lateral single-position surgery platform which is intended to increase OR efficiency by reducing the need for patient repositioning which may result in a patient being under anesthesia for a decreased amount of time.
"NuVasive pioneered the lateral approach in spine surgery, and continues to lead the industry with disruptive procedural solutions that maximize the efficiency of these less invasive techniques while retaining the inherent benefits to surgeons, patients and hospitals," said Matt Link, president, Strategy, Technology and Corporate Development for NuVasive. "Brigade Lateral is no exception, and extends our comprehensive procedural offering to a wider range of indications from the lateral approach."
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, focused on transforming spine surgery and beyond with minimally disruptive, procedurally integrated solutions designed to deliver reproducible and clinically-proven surgical outcomes. The Company's portfolio includes access instruments, implantable hardware, biologics, software systems for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative monitoring service offerings. With over $1 billion in revenues, NuVasive has an approximate 2,400-person workforce in more than 40 countries serving surgeons, hospitals and patients. For more information, please visit www.NuVasive.com.
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products (including the iGA® platform), the Company's ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.